"The property tax base for the construction of this future oncology drug manufacturing plant has been validated by the competent services, which will enable us to lay the foundation stone of this production unit before the end of the year, "Ipsen Pharma-Algeria CEO Adlane Soudani told a press conference held jointly by the leaders of the French group Ipsen and their financial partner Isly Holding, an Algerian company chaired by Lyes Boudiaf who intervenes in industrial partnerships.
This "high value-added" investment of 20 million euros is for the manufacture of an injectable drug, Decapeptyl (triptorelin), indicated for the treatment of prostate cancer, the third type of male cancers in Algeria, according to the explanations of Mr. Soudani, who refers to data from the National Cancer Plan 2015-2019.
In addition to the treatment of prostate cancer, "this same drug has other indications such as the treatment of precocious puberty and certain diseases affecting women such as endometriosis, uterine fibroids and female infertility", he added.
For his part, the vice-president of Operation Intercontinental Family Health Guillaume Freneuil, said that the plant should go into production in 2021, saying that "three years is the usual time to achieve this kind of project . "
He explained in this sense that "the priority for the moment was to ensure that the plant was operational on time with the capacity to cover all the needs of the local market".
Once this goal is achieved, he continued, "we can then think about exporting."
In addition to the therapeutic and commercial aspect, namely the guarantee of the availability of the drug and the reduction of the import bill, the speakers referred to the transfer of know-how.
In this context, the Executive Vice President of the Ipsen Group, Benoit Hennion, underlined the fact that the future factory that will be established in Algeria, will be the second factory of Ipsen specialized in the production of anti-cancer, after that of France, emphasizing that there is a clear commitment for technology transfer deposited with the Ministry of Health, Population and Hospital Reform.
In this regard, he said that about a hundred employees were "transferred" from the French factory to the joint venture to realize such a project of this scale.
"There are highly qualified skills, experts who will ensure the transfer of technology by training engineers, pharmacists, chemists and microbiologists," he assured, stating that he would have a 50 or so people working in this factory.
As a reminder, the shareholding agreement for the creation of this joint company was signed on December 7, 2017 in Paris, on the occasion of the meeting of the France-Algeria Interministerial High Level Committee (CIHN), and in accordance with Rule 51/49.
The employees signed on this occasion the transfer of their contracts to the newly created joint venture Ipsen Pharma Algérie SPA
Currently, the Ipsen group markets more than 20 drugs in more than 115 countries, with direct commercial presence in more than 30 countries, according to the leaders of this pharmaceutical group.
Ipsen develops and commercializes innovative drugs in three targeted therapeutic areas: oncology, neuroscience and rare diseases.
In 2017, Ipsen achieved a turnover of 1.9 billion euros.